ABOS
Acumen Pharmaceuticals Inc

1,140
Mkt Cap
$120.54M
Volume
588,284.00
52W High
$2.46
52W Low
$0.8551
PE Ratio
-0.84
ABOS Fundamentals
Price
$1.86
Prev Close
$1.99
Open
$1.95
50D MA
$1.96
Beta
1.54
Avg. Volume
164,093.95
EPS (Annual)
-$1.71
P/B
1.21
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Acumen Pharmaceuticals (NASDAQ:ABOS) CFO Matt Zuga Sells 5,100 Shares
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 5,100 shares of the business's stock in a transaction dated Tuesday, January 6th. The stock was sold at an average...
MarketBeat·12h ago
News Placeholder
More News
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded at Wall Street Zen
Wall Street Zen upgraded Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Sunday...
MarketBeat·19d ago
News Placeholder
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Average Recommendation of "Moderate Buy" from Analysts
Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the company...
MarketBeat·23d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen downgraded Acumen Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·27d ago
News Placeholder
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Consensus Rating of "Moderate Buy" by Brokerages
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, MarketBeat reports. One...
MarketBeat·2mo ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Cut to $8.00 by Analysts at Bank of America
Bank of America cut their price objective on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday...
MarketBeat·2mo ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Acumen Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·2mo ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of...
MarketBeat·2mo ago
News Placeholder
Preview: Acumen Pharmaceuticals's Earnings
read more...
Benzinga·2mo ago
<
...
1
>

Latest ABOS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.